GLRX and metabolic dysfunction-associated steatohepatitis: To determine whether increased expression of Glrx could attenuate these effects, we injected AAV-Hep-Glrx or AAV-Hep-control vectors after 20 weeks of the NASH diet, when fibrosis had already appeared and continued the diet for another 12 weeks (Figure 5A).